Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi-Sankyo announces first presentation of study

Daiichi-Sankyo announces first presentation of study

12th November 2008

Daiichi-Sankyo has announced the first presentation of a study into paediatric patients.

The research saw the supporting of the use of colesevelam HCI in paediatric patients with heterozygous familial hypercholstrolemia (heFH) and was presented at the American Heart Association’s Annual Scientific Sessions 2008.

According to the study’s findings, colesevelam HCI was well-tolerated and produced a significant reduction in low density lipoprotein (LDL) or bad cholesterol when used as monotherapy, or in combination with a statin.

The efficacy of colesevelam HCI 3.75g/day as monotherapy or in combination with a statin was also evaluated in an eight week randomised study of paediatric patients with heFH, followed by applying them through an 18 week open-label treatment period.

Director of the Metabolic & Atherosclerosis Research Centre in Cincinnati, US, Evan Stein, said: “Treatment with colesevelam HCl in paediatric patients with inherited high cholesterol significantly reduced their LDL or ?bad? cholesterol and increased the HDL or ?good? cholesterol.”

He added that the effects were seen in children who received colesevelam HCl either alone or combined with a statin, which in turn shows the additive effect on LDL-cholestrol reduction performed by colesevelam HCl therapy.

There are currently approximately ten million people with FH worldwide, of which the majority have heterozygous FH.2.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.